Eicosanoids in inflammatory bowel disease therapeutic implications

Clinical Immunotherapeutics

Volumn 6, Issue 5, 1996, Pages 333-340

  Casellas, Francesc ^a   Guarner, Francisco ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FISH OIL; ICOSANOID; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E; SALAZOSULFAPYRIDINE;

DIET; ENTERITIS; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029845822     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259354     Document Type: Article

References (73)

1. Higgs GA, Moncada S, Vane JR. Eicosanoids in inflammation. Ann Clin Res 1984; 16: 287-99
2. Whittle BJR, Kauffman GL, Moncada S. Vasoconstriction with thromboxane A: induces ulcération of the gastric mucosa. Nature 1981; 292: 472-4
3. Guarner F, Fremont-Smith M, Prieto J. Cytoprotective effects of prostaglandins on isolated liver cells. Liver 1985; 5: 35-9
4. Lewis GP. Immune-regulatory activity of metabolites of arachidonic acid and their role in inflammation. Br Med Bull 1983; 39: 243-8
5. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237: 1171-6
6. Henderson WR. The role of leukotrienes in inflammation. Ann Intern Med 1994; 121: 684-97
7. Sharon M, Karmeli F, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis: enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978:75:638-40
8. Ligumsky M, Karmeli F, Sharon P, et al. Enhanced thromboxane A: and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81: 444-9
9. Boughton-Smith NK, Hawkey CJ, Whittle BJR. Biosynthesis of lipoxygenase and cyclo-oxygenase products from (]4C) arachidonic acid by human colonie mucosa. Gut 1983; 24: 1176-82
10. Casellas F, Guarner F, Rodriguez R, et al. Human jejunal LTC4 response to irritant bile acids. Eur J Gastroenterol Hepatol 1991:3:393-7
11. Casellas F, Papo M, Guarner F, et al. Intraluminai colonie release of immunoreactive tumour necrosis factor in chronic ulcerative colitis. Clin Sei 1994; 87: 453-8
12. Lauritsen K, Laursen LS, Bukhave K, et al. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin £2 and leukotriene 64 determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986:91: 837-46
13. Zipser RD, Nast CC, Lee M, et al. In vivo production of leukotriene 64 and leukotriene C4 in rabbit colitis. Gastroenterology 1987:92: 33-9
14. Vilaseca J, Salas A, Guarner F, et al. Participation of thromboxane and othereicosanoid synthesis in the course of experimental inflammatory colitis. Gastroenterology 1990: 98: 269-77
15. Rampton DS, Hawkey CJ. Prostaglandins and ulcerative colitis. Gut 1984:25: 1399-413
16. Zifroni A, Trêves AJ, Sachar DB, et al. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut 1983; 24: 659-64
17. Rachmilewitz D, Ligumsky M, Haimovitz A, et al. Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory bowel disease. Gastroenterology 1982; 82: 673-9
18. Lauritsen K, Laursen LS, Bukhave K, et al. In vivo effects of orally administered prednisolone on prostaglandin and leukotriene production in ulcerative colitis. Gut 1987; 28: 1095-9
19. Lauritsen K, Laursen LS, Bukhave K, et al. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology 1988; 95: 11-7
20. Casellas F, Guarner F, Rodn'guez R, et al. Abnormal jejunal prostanoid release in response to mucosal irritation in chronic ulcerative colitis. Eur J Gastroenterol Hepatol 1991; 3:667-73
21. Casellas F, Guarner F, Antoli'n M, et al. Abnormal leukotriene C4 release by unaffected jejunal mucosa in patients with inactive Crohn's disease. Gut 1994; 35: 517-22
22. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with nonsteroidal antiinflammatory drugs. Postgrad Med J 1981; 57: 297-9
23. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107:513-6
24. Walt RP, Hawkey CJ, Langman MJS. Colitis associated with non-steroidal anti-inflammatory drugs. BMJ 1984; 288: 238
25. Leaf A, Weber PC. Cardiovascular effects of n - 3 fatty acids. N Engl J Med 1988; 318: 549-57
26. Needleman P, Raz A, Minkes MS, et al. Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sei USA 1979; 76: 944-8
27. Siess W, Roth P, Scherer B, et al. Platelet membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet. Lancet 1980; I: 441-4
28. Fischer S, Weber PC. Thromboxane A3 is formed in human platelets after dietary eicosapentaenoic acid (2O:5o)3). Biochem Biophys Res Commun 1983: 116: 1091-9
29. Croff KD, Bellin LJ, Legge FM, et al. Effects of diets enriched in eicosapentaenoic or docosahexaenoic acids on prostanoid metabolism in the rat. Lipids 1987; 22: 647-50
30. Lee TH. Hoover RL. Williams JD, et al. Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophii and monocyte leukotriene generation and neulrophil function. N Engl J Med 1985: 312: 1217-24
31. Sperling RI. Weinblatt M. Robin JL, et al. Effects of dietary supplementation with marine fish oil on leukocyte lipid mediator generation and function in rheumatoid arthritis. Arthritis Rheum 1987; 30: 988-97
32. Kremer JL, Jubi W, Michalek A, et al. Fish-oil fatty acid supplementation in active rheumatoid arthritis. Ann Intern Med 1987; 106: 497-503
33. Grant HW. Palmer KR, Kelly RW. et al. Dietary linoleic acid, gastric acid and prostaglandin secretion. Gastroenterology 1988; 94: 955-9
34. Prichard P. Brown G. Bhaskar N. et al. The effect of dietary fatty acids on the gastric production of prostaglandins and aspirin-induced injury. Aliment Pharmacol Ther 1988: 2: 179-84
35. Schepp W. Steffen B. Ruoff HJ. et al. Modulation of rat gastric mucosal prostaglandin E2 release by dietary linoleic acid: effects on gastric acid secretion and stress-induced mucosal damage. Gastroenterology 1988:95: 18-25
36. Guarner F. Vilaseca J. Malagelada J-R. Dietary manipulation in experimental inflammatory bowel disease. Agents Actions 1992; CKM
37. Lugea A. Videla S. Vilaseca J. el al. Antiulcerogenic and antiinflammatory actions of fatty acids on the gastrointestinal tract. Prostaglandins Leukot EssentFatty Acids 1991:43: 135-40
38. Vilaseca J. Salas A. Rodrîguez R. et al. Dietary fish oil reduces progression of chronic inflammatory lesions in a rat model of granulomatous colitis. Gut 1990; 31: 539-44
39. Bloch KJ. Ho B. Lian L. et al. Effect of fish-fat or beef-fat supplemented diet on immune complex-induced enteropathy in the rat. Prostaglandins 1989: 38: 385-96
40. Hawthorne AB. Willars TJ. Daneshmend TK. et al. Fish oil in the treatment of ulcerative colitis: biochemical consequences I abstract]. Gastroenterology 1988: 94: A177
41. Hillier K. Jewel! R. Dorreil L. et al. Incorporation of fatty acids from fish oil and olive oil into colonie mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991; 32: 1151-5
42. McColl T. O Leary D. Bloomtield J. et al. Eicosapentaenoic acid [abstract). Gaslroenterology 1988: 94: A294
43. Hawthorne AB. Daneshmend TK. Hawkey CJ. et al. Fish oil in ulceratixe colitis: final results of a controlled clinical trial [abstract!. Gastroenterology 1990; 98: A174
44. Salomon P. Kornbluth A. Janowitz HD. Maintenance of remission in ulcerative colitis using fish oil omega-3 tatty acid | abstract |. Gastroenterology 1990; 98: A201
45. Tobin A. Suzuki Y. O'Morain C. Controlled double blind cross over study of eicosapentaenoic acid (EPA) in chronic ulcerative colitis (UC) [abstract]. Gastroenterology 1990; 98: A207
46. Stenson WF. Cort D. Bceken W. et al. A trial of fish oil supplemented diet in ulcerative colitis [abstract!. Gastroenteroloey 1990: 98: A475
47. Salomon P. Kornbluth A. Janowitz HD. Treatment of ulcerative colitis with fish oil n-3-omega-fatty acid: an open trial. J Clin Gastroenterol 1990; 12: 157-61
48. Stenson WF. Cort D. Rodgers J. el al. Dietary supplementation with fish oil in ulcerative colitis. Ann intern Med 1992; 116: 609-14
49. Hawthorne AB, Daneshmend TK. Hawkey CJ. et al. Treatment ot ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992: 33: 922-8
50. Asian A. Triadafilopoulos G. Fish oil tatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 1992; 87: 432-7
51. Greenfield SM. Green AT. Teare JP, et al. Final results of a controlled trial of fatty acid supplementation in maintenance treatment of ulcerative colitis [abstract]. Gastroenterology 1992; 102: A631
52. Belluzzi A. Brignola C. Campieri M, et al. New fish oil derivate for preventing clinical relapses in Crohn's disease: a double blind placebo controlled randomized trial (abstract]. Gastroenterology 1995; 108: A78I
53. Scheurlen M. Daiss W, Steinhilber D, et al. Effects of longterm application offish oil in patients with Crohn's disease. Scand J Gastroenterol 24 Suppl. 158: 100-1
54. Esteve-Comas M. Ramire?. M, Fernândez-Banares F. et al. Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease. Gut 1992:33: 1365 9
55. Laursen LS. Naesdal J. Bukhave K, et al. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335: 683 5
56. Collawn C. Rubin P. PèreJ. N, et al. Experimental use of a 5lipoxygenase inhibitor (Ahbott-64077) in human ulcerative colitis (UC). Am J Gastroenterol 19X9: 84: 1178
57. Lauritsen K. Laursen LS. Rask-Madsen J, et al. Abbott-64077. a potent lipoxygenase inhibitor in the treatment of ulcerative colitis [abstract!. Gastroenterology 1990: 98: A185
58. Peppercorn M. Das K. ElsonC. et al. Zileuton, a 5-lipoxygenase inhibitor, in the treatment of active ulcerative colitis: a double-blind, placebo-controlled trial |abstract|. Gastroenterology 1994; 106: A75I
59. Hawkey C. Gassull M, Lauritsen K. et al. Efficacy of zileuton. a 5-lipoxygenase inhibitor, in the maintenance of remission in patients with ulcerative colitis (abstract]. Gastroenterology 1994; 106: A697
60. Dailianas A. Spialiadis L. Gianikaki L. et al. Efficacy of an inhibitor of leukotrienes production in patients with ulcerative colitis in remission (abstract!. Gastroenterology 1995; 108: A805
61. Kieldsen J. Laursen LS. Hillingso J. et al. Blockade of leuko triene production by a single dose of FPL 64I70XX 0.5<< enema in active ulcerative colitis |abstract|. Gastroenterologv 1995: 108: A849
62. Murthy SN. Murthy S. Wood JD. BAY-Y-1015. a 5lipoxygenase (5-LOl activating protein (FLAP) inhibitor, inhibits inflammation and disease activity in dextran sulfate (DSS)-rnediated mouse experimental colitis (abstract]. Gastroenterology 1995: 108: A882
63. Taniguchi T. Tsukada H, Nakamura H. el al. Effect of thromboxane A2 receptor antagonist (ONO-NT-126) on an animal model of inflammatory bowel disease (abstract]. Gastroenterology 1995: 108: A926
64. Banerjee AK. Peters TJ. Experimental non-steroidal antiinflammatory drug-induced cnteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxanc synthetase inhibitors. Gut 1990:31: 1358-64
65. Van Dullemen HM, Tytgat SHA. Strijbos M. et al. Bioavailability of ridogrel administered orally and rectally to patients with ulcéraiive colitis (abstract], Gastroenterology 1995; 108: A933
66. Casellas F. Papo M. Guarner F. et al. Effects of thromboxane synlhase inhibition on in uw> release of inflammatory mediators in chronic ulcerative colitis. EurJ Gastroenterol Hepatol 1995; 7: 221-6
67. Collins CE, Forbes A, Rampton DS. Anti-platelet therapy in active Crohn's disease: an open trial using picotamide, a thromboxane antagonist [abstract]. Gastroenterology 1995; 108: A799
68. Wallace JL, Keenan CM, Gale D, et al. Exacerbation of experimental colitis by nonsteroidal anti-inflammatory drugs is not related to elevated ieukotriene 84 synthesis. Gastroenterology 1982; 102: 18-27
69. Hoult JRS, Moore PK. Sulfasalazine is a potent inhibitor of prostaglandin 15-hydroxydehydrogenase: possible basis for therapeutic action in ulcerative colitis. Br J Pharmacol 1978; 64: 6-8
70. Hoult JRS, Moore PK. Effects of sulphasalazine and its metabolites on prostaglandin synthesis, inactivation and actions on smooth muscle. BrJ Pharmacol 1980; 68: 719-30
71. Greenfield SM, Punchard NA, Boswell DJ, et al. Aminosalicylate therapy increases prostaglandin production in ulcerative colitis. Gut 1993; 34: S52
72. Goldin E, Rachmilewitz D. Prostanoids cytoprotection t'or maintaining remission in ulcerative colitis. Dig Dis Sei 1983; 28: 807-11
73. Kornbluth A, Gupta R, Gerson CD. Life-threatening diarrhea after short-term misoprostol use in a patient with Crohn ileocolitis. Ann Intern Med 1990: 113: 474-5